|
3.1.2022 |
EN |
Official Journal of the European Union |
C 2/30 |
Judgment of the General Court of 10 November 2021 — Stada Arzneimittel v EUIPO — Pfizer (RUXXIMLA)
(Case T-239/20) (1)
(EU trade mark - Opposition proceedings - Application for the EU word mark RUXXIMLA - Earlier EU word mark RUXIMERA - Relative ground for refusal - Likelihood of confusion - Similarity of the signs - Article 8(1)(b) of Regulation (EU) 2017/1001)
(2022/C 2/39)
Language of the case: English
Parties
Applicant: Stada Arzneimittel AG (Bad Vilbel, Germany) (represented by: J.-C. Plate and R. Kaase, lawyers)
Defendant: European Union Intellectual Property Office (represented by: D. Gája, acting as Agent)
Other party to the proceedings before the Board of Appeal of EUIPO, intervener before the General Court: Pfizer Inc. (New York, New York, United States) (represented by: V. von Bomhard and J. Fuhrmann, lawyers)
Re:
Action brought against the decision of the Fourth Board of Appeal of EUIPO of 13 February 2020 (Case R 1879/2019-4), relating to opposition proceedings between Pfizer and Stada Arzneimittel.
Operative part of the judgment
The Court:
|
1. |
Dismisses the action; |
|
2. |
Orders Stada Arzneimittel AG to pay the costs. |